332 related articles for article (PubMed ID: 2529199)
1. Levels of protein S during the normal menstrual cycle and in women on oral contraceptives low in estrogen.
Jespersen J; Nielsen MT
Gynecol Obstet Invest; 1989; 28(2):82-6. PubMed ID: 2529199
[TBL] [Abstract][Full Text] [Related]
2. Comparison of contraceptive acceptability of levonorgestrel and ethinyl oestradiol administered in one three-phasic (Trionetta) and one monophasic (Neovletta) version.
Carlborg L
Contraception; 1983 May; 27(5):439-52. PubMed ID: 6349925
[TBL] [Abstract][Full Text] [Related]
3. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
[TBL] [Abstract][Full Text] [Related]
4. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
Notelovitz M; Kitchens CS; Khan FY
Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
[TBL] [Abstract][Full Text] [Related]
5. Sequential study of plasma euglobulin fibrinolytic activity during the normal menstrual cycle and in women on oral contraceptives low in estrogen.
Jespersen J
Gynecol Obstet Invest; 1983; 15(5):266-74. PubMed ID: 6852646
[TBL] [Abstract][Full Text] [Related]
6. Contraception in older woman.
Volpe A; Silferi M; Genazzani AD; Genazzani AR
Contraception; 1993 Mar; 47(3):229-39. PubMed ID: 8462314
[TBL] [Abstract][Full Text] [Related]
7. The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status.
Larsson G; Milsom I; Lindstedt G; Rybo G
Contraception; 1992 Oct; 46(4):327-34. PubMed ID: 1486771
[TBL] [Abstract][Full Text] [Related]
8. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
9. Cycle control with triphasic norgestimate and ethinyl estradiol, a new oral contraceptive agent.
Andolsek KM
Acta Obstet Gynecol Scand Suppl; 1992; 156():22-6. PubMed ID: 1324553
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel.
Lemay A; Dewailly SD; Grenier R; Huard J
J Clin Endocrinol Metab; 1990 Jul; 71(1):8-14. PubMed ID: 2142494
[TBL] [Abstract][Full Text] [Related]
11. Individual levels of plasma histidine-rich glycoprotein (HRG) during the normal menstrual cycle and in women on oral contraceptives low in oestrogen.
Jespersen J; Kluft C
Scand J Clin Lab Invest; 1982 Nov; 42(7):563-6. PubMed ID: 6818678
[TBL] [Abstract][Full Text] [Related]
12. Metabolic effects of combined oral contraceptive preparations.
Singh BM; Nutter SA; Nattrass M
Contraception; 1987 Dec; 36(6):651-8. PubMed ID: 3128428
[TBL] [Abstract][Full Text] [Related]
13. Pulsatile luteinizing hormone patterns in long term oral contraceptive users.
Hemrika DJ; Slaats EH; Kennedy JC; de Vries Robles-Korsen TJ; Schoemaker J
J Clin Endocrinol Metab; 1993 Aug; 77(2):420-6. PubMed ID: 8345046
[TBL] [Abstract][Full Text] [Related]
14. Effect of some oral contraceptives on serum concentrations of sex hormone binding globulin and ceruloplasmin.
Song S; Chen JK; He ML; Fotherby K
Contraception; 1989 Apr; 39(4):385-99. PubMed ID: 2498034
[TBL] [Abstract][Full Text] [Related]
15. An investigation into the effect of tenidap sodium on the pharmacokinetics of a combined oral contraceptive.
Coates PE; Mesure R
Br J Clin Pharmacol; 1995; 39 Suppl 1(Suppl 1):47S-50S. PubMed ID: 7547095
[TBL] [Abstract][Full Text] [Related]
16. Plasma concentrations of vasopressin and a prostaglandin F2 alpha metabolite in women with primary dysmenorrhoea before and during treatment with a combined oral contraceptive.
Hauksson A; Akerlund M; Forsling ML; Kindahl H
J Endocrinol; 1987 Nov; 115(2):355-61. PubMed ID: 3125302
[TBL] [Abstract][Full Text] [Related]
17. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
[TBL] [Abstract][Full Text] [Related]
18. Postponement of withdrawal bleeding in women using low-dose combined oral contraceptives.
Hamerlynck JV; Vollebregt JA; Doornebos CM; Muntendam P
Contraception; 1987 Mar; 35(3):199-205. PubMed ID: 2956054
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of a new triphasic oral contraceptive: norgestimate and ethinyl estradiol.
Gauthier A; Upmalis D; Dain MP
Acta Obstet Gynecol Scand Suppl; 1992; 156():27-32. PubMed ID: 1324554
[TBL] [Abstract][Full Text] [Related]
20. Cyclic fluctuations in human serum lipid and apolipoprotein levels during the normal menstrual cycle: comparison with changes occurring during oral contraceptive therapy.
Lussier-Cacan S; Xhignesse M; Desmarais JL; Davignon J; Kafrissen ME; Chapdelaine A
Metabolism; 1991 Aug; 40(8):849-54. PubMed ID: 1907348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
